Medical Care Technologies Receives First Human Volunteer Datasets for Melanoma Scan Beta Testing

Medical Care Technologies Inc. has received its first human volunteer image datasets for the beta testing of its Melanoma Scan application. This development marks a significant step in the company's efforts to refine the AI-assisted imaging and body-map monitoring tool beyond its initial testing on public cancer imaging archives.

The datasets, submitted by volunteers, will enable the company to evaluate the application's performance in real-world conditions. These conditions include variations in lighting, device type, distance, angle, and image quality, which are not fully replicable in public archives. The collected images will help in assessing how the application handles different skin appearances and the organization of body maps over time.

"We asked for volunteer-submitted images so that Melanoma Scan Beta could be evaluated against the way people actually take photos. The first datasets are now in hand, which is a major step up from public archives alone."

Until this phase, the development of Melanoma Scan Beta focused on structured internal testing and model evaluation using established public dermatology resources, including the HAM10000, ISIC Archive collections, and TCIA melanoma cohorts. The introduction of real-world user-submitted images is expected to provide valuable insights into the application's performance and usability in everyday scenarios.

The platform remains in beta-stage development and has not received regulatory clearance. It is not intended to treat, cure, or prevent any disease or medical condition. It is also not a substitute for professional medical advice or evaluation by a qualified healthcare provider. Any concern about a skin change should be reviewed by a licensed clinician.

Medical Care Technologies Inc. is a diversified technology company focused on the development and commercialization of artificial intelligence-powered applications spanning health, wellness, nutrition, lifestyle, and enterprise imaging analysis solutions. The company continues to advance its testing protocol as additional volunteer-submitted images are collected and reviewed.

The company's next steps will involve evaluating the image intake process, body-map organization, and longitudinal comparison of the same mapped skin area over time. These evaluations will help refine the application to better serve its intended purpose of helping users catalog visible skin images and review possible visual changes across successive sessions.